Scancell (LON:SCLP - Get Free Report) issued its quarterly earnings data on Thursday. The company reported GBX (1.26) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
Scancell Stock Performance
Shares of LON:SCLP traded up GBX 0.55 on Tuesday, hitting GBX 9.80. 1,912,970 shares of the company were exchanged, compared to its average volume of 1,034,792. Scancell has a 1-year low of GBX 7.26 and a 1-year high of GBX 18. The stock's 50 day moving average price is GBX 10.04 and its 200 day moving average price is GBX 9.64. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. The firm has a market capitalization of £101.70 million, a P/E ratio of -471.15 and a beta of 0.35.
Insider Activity at Scancell
In related news, insider Martin Diggle acquired 3,150,000 shares of the stock in a transaction dated Friday, September 12th. The stock was acquired at an average cost of GBX 9 per share, for a total transaction of £283,500. Insiders have acquired 7,652,236 shares of company stock worth $73,474,596 in the last three months. Insiders own 15.15% of the company's stock.
About Scancell
(
Get Free Report)
Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
See Also
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
